Aprocitentan
- Generic Name
- Aprocitentan
- Brand Names
- Jeraygo
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14Br2N6O4S
- CAS Number
- 1103522-45-7
- Unique Ingredient Identifier
- MZI81HV01P
- Background
Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).
A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects
- First Posted Date
- 2016-07-22
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02841761
- Locations
- ๐บ๐ธ
Investigator Site, Newark, New Jersey, United States
Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02708004
- Locations
- ๐จ๐ญ
Investigator Site Lausanne, Lausanne, Switzerland
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
Phase 2
Completed
- Conditions
- Essential Hypertension
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 1659
- Registration Number
- NCT02603809
- Locations
- ๐บ๐ธ
LCC Medical Research Institute, Miami, Florida, United States
๐บ๐ธAllied Biomedical Research Institute, INC, Miami, Florida, United States
๐บ๐ธMidwest Institute for Clinical Research, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath